OncoMatch/Clinical Trials/NCT06770452
HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients
Is NCT06770452 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies multiple treatments including HRS-4642 and Nimotuzumab for metastatic pancreatic carcinoma.
Treatment: HRS-4642 · Nimotuzumab · gemcitabine + nab-paclitaxel — This study is a single-arm phase II clinical study to include 32 patients with advanced pancreatic cancer with KRAS G12D mutation to evaluate the effectiveness of HRS-4642 combined with nitutuzumab and AG for first-line treatment of advanced pancreatic cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Pancreatic Cancer
Biomarker criteria
Required: KRAS g12d
Tumor tissue contains KRAS G12D mutation
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: targeted therapy against KRAS G12D
Previous treatment of targeted therapy against KRAS G12D
Cannot have received: targeted therapy against EGFR
Previous targeted therapy against EGFR
Cannot have received: systemic antitumor therapy in advanced stage
Exception: if previous neoadjuvant / adjuvant therapy, last treatment should be over 6 months
No systemic antitumor therapy in advanced stage; if previous neoadjuvant / adjuvant therapy, last treatment should be over 6 months
Lab requirements
Blood counts
Neutrophil count ≥1.5×10^9 / L; Platelet ≥100×10^9 / L; Hemoglobin ≥100 g / L; Serum albumin ≥30 g / L
Kidney function
Creatinine clearance ≥50 mL/min or serum creatinine ≤1.5×ULN; Urinary protein <2+; if urine protein ≥2+, 24 hours urine protein quantification <1g can be enrolled
Liver function
Total bilirubin ≤1.5×ULN; ALT, AST ≤3×ULN and ALP ≤2.5×ULN; if the patient has liver metastasis, ALT, ALT and AST ≤5×ULN; if the patient has liver or bone metastasis, ALP ≤5×ULN
Cardiac function
ECG: QTcF ≤450 ms (male), QTcF ≤470 ms (female); Cardiac color ultrasound: LVEF ≥50%
The functions of vital organs meets the following requirements (any blood components, cell growth factors are not allowed 2 weeks prior to enrollment): ... [full details as above]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06770452 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior targeted therapy against KRAS G12D, targeted therapy against EGFR, systemic antitumor therapy in advanced stage disqualifies patients from enrollment.
Does this trial require KRAS?
Yes, KRAS g12d is a required biomarker for enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages